ID   BALM-18
AC   CVCL_5694
DR   JCRB; JCRB1796
DR   Wikidata; Q54753133
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=10374849;
CC   Population: Japanese.
CC   Virology: EBV-negative.
CC   Doubling time: 36 hours (PubMed=10374849).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): JCRB=JCRB1796
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D5S818: 10,13
ST   D7S820: 11,12
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 17,20
DI   NCIt; C7954; Adult Burkitt leukemia
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 15
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=10374849; DOI=10.1016/S0145-2126(99)00046-6;
RA   Matsuo Y., Sugimoto A., Harashima A., Nishizaki C., Ishimaru F.,
RA   Kondo E., Katayama Y., Harada M., Orita K.;
RT   "Establishment and characterization of a novel ALL-L3 cell line (BALM-18):
RT   induction of apoptosis by anti-IgM and inhibition of apoptosis by bone
RT   marrow stroma cells.";
RL   Leuk. Res. 23:559-568(1999).
//